FDA Releases Guidance for Clinical Trials of RSV Drugs

Clinical Trials Advisor
A A
Developers of antiviral drugs for prophylaxis and treatment of respiratory syncytial virus should expose at least 100 adults in clinical trials ahead of pediatric studies, the FDA said in new guidance for drugmakers.

To View This Article:

Login

Subscribe To Clinical Trials Advisor